BGM
STRO icon

Burkehill Global Management’s Sutro Biopharma STRO Stock Holding History

Burkehill Global Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71,530
Closed -$1.78M – 213
2026
Q1 		$1.78M Buy
+71,530
New +$1.29M 0.09% 130

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Burkehill Global Management's STRO Position: Q2 2026 in Review

Burkehill Global Management sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 71,530 shares — an estimated $1.78M sold.

Burkehill Global Management first reported a position in STRO in Q1 2026 and held it in 1 quarter. The position peaked at $1.78M in Q1 2026. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Burkehill Global Management reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
  • Burkehill Global Management sold 71,530 Sutro Biopharma shares in Q2 2026, an estimated $1.78M.
  • Burkehill Global Management first reported a position in Sutro Biopharma in Q1 2026 and held it in 1 quarter.
  • Burkehill Global Management's Sutro Biopharma position peaked at $1.78M in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.